Leveraging liquid biopsy testing in cancer clinical trials can help overcome potential limitations of a tissue-only approach and set a new gold standard in precision oncology. A paired tissue-plasma strategy can not only uncover therapeutically targetable mutations that tissue-only testing misses, but also increase eligible patient populations and enhance testing access and flexibility.1
It’s clear the future includes plasma. Although introducing plasma-based clinical trial assays can augment traditional tissue-based testing workflows and findings, it will require a thoughtful approach to your trial strategy and design. Gain a deeper understanding of the regulatory considerations and how to address them for a seamless research experience.